Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.58 |
| ▸ | HRH1 | P35367 | 9/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11144393 | 0.86 | CYP1A2 (0.58) | HTR2AHRH1HTR2CHDAC4HDAC7 | |
| SCHEMBL8746509 | 0.84 | HTR2A (0.52) | HTR2AHRH1HTR2C | |
| SCHEMBL13343950 | 0.82 | HTR2A (0.43) | HTR2AHRH1HTR2C | |
| SCHEMBL18352989 | 0.81 | HTR2A (0.45) | HTR2AHRH1HTR2CANPEP | |
| SCHEMBL2187484 | 0.81 | ANPEP (0.59) | HTR2AHRH1HTR2CHDAC4HDAC7 | |
| SCHEMBL30633009 | 0.81 | ANPEP (0.59) | HTR2AHRH1HTR2CHDAC4HDAC7 | |
| SCHEMBL22879435 | 0.80 | BCHE (0.47) | HTR2AHRH1ANPEP | |
| SCHEMBL2600798 | 0.78 | HTR2A (0.37) | HTR2AHRH1HTR2C | |
| SCHEMBL12401932 | 0.78 | DRD2 (0.46) | HTR2A | |
| SCHEMBL18943757 | 0.78 | HTR2A (0.47) | HTR2AHRH1HTR2CANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991008190-A1 | AMINO ACID PROTECTING GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-06-13 | — | — | WO | claimed |
| US-10685844-B2 | Hardmask composition, method of forming pattern by using the hardmask composition, and hardmask formed using the hardmask composition | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-06-16 | — | — | US | disclosed |
| US-20190035635-A1 | HARDMASK COMPOSITION, METHOD OF FORMING PATTERN BY USING THE HARDMASK COMPOSITION, AND HARDMASK FORMED USING THE HARDMASK COMPOSITION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-01-31 | — | — | US | disclosed |
| US-5101059-A | Xanthene compounds | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| WO-1991008190-A1 | AMINO ACID PROTECTING GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
| US-4152356-A | SELECTIVE CARBONYLATION OF 9,10-DIHYDROANTHRACENE TO FORM 9-FORMYL-9,10-DIHYDROANTHRACENE | EXXON RESEARCH & ENGINEERING CO. (US) | 1979-05-01 | — | — | US | disclosed |
| US-4131646-A | Preparation of hydrogen peroxide from dihydroanthracene hydroperoxides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190035635-A1 | HARDMASK COMPOSITION, METHOD OF FORMING PATTERN BY USING THE HARDMASK COMPOSITION, AND HARDMASK FORMED USING THE HARDMASK COMPOSITION | DEK, HNRNPK, DGKA | HTR2A 4854/4885HRH1 4021/4885HTR2C 4710/4885 |
| US-10685844-B2 | Hardmask composition, method of forming pattern by using the hardmask composition, and hardmask formed using the hardmask composition | DEK, HNRNPK, DGKA | HTR2A 4854/4885HRH1 4021/4885HTR2C 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.